摘要
Abstract
OBJECTIVE:To probe into the clinical effects of cinacalcet in treatment of hemodialysis patients with secondary hyperparathyroidism .METHODS: 110 hemodialysis patients with secondary hyperparathyroidism admitted into Shenzhen the Second People's Hospital were selected to be divided into observation group and control group via the random number table, with 55 cases in each.The control group were treated with phosphate binder and vitamin D analogues , while the observation group additionally received cinacalcet based on the control group .The level of parathyroid hormone (PTH), calcium concentration, phosphorus concentration, level of fibroblast growth factor 23 (FGF23) and level of bone specific alkaline phosphatase (BSAP) in two groups were observed.RESAULTS:After treatment of 23 weeks, the level of PTH, calcium concentration , phosphorus concentration , level of FGF23 and level of BSAP decreased , and the data of observation group were lower than control group , with statistically difference (P<0.05).The total effective rate of observation group was 83.6%(46/55), significantly higher than that of control group [54.5 (30/55)], with statistically difference (χ2 =10.89,P=0.001).The adverse drug reactions in two groups were mild , yet there was no difference in the incidence of adverse drug reactions (P >0.05).CONCLUSIONS: Cinacalcet can reduce the level of PTH, calcium concentration, phosphorus concentration , level of FGF23 and level of BSAP .The clinical efficacy is significant with low incidence of adverse drug reactions .It is worthy of clinical application and promotion .关键词
西那卡塞/血液透析/甲状旁腺功能亢进Key words
Cinacalcet/Hemodialysis/Hyperparathyroidism分类
药学
